Molecular Partners to Regain Global Rights for MP0310 from Amgen
26. April 2022 16:05 ET
|
Molecular Partners
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., April 26, 2022 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR: Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage...
Molecular Partners Provides Update on Ensovibep Following Novartis Quarterly Earnings Call
26. April 2022 14:00 ET
|
Molecular Partners
ZURICH-SCHLIEREN, Switzerland & CONCORD, Mass., April 26, 2022 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR: Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage...
Molecular Partners Announces Presentation of the EMPATHY Study of Ensovibep for the Treatment of COVID-19 at ECCMID 2022
23. April 2022 01:00 ET
|
Molecular Partners
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., April 23, 2022 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of...
Molecular Partners to Present at Kempen Life Sciences Investor Conference
13. April 2022 12:00 ET
|
Molecular Partners
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., April 13, 2022 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of...
Molecular Partners Announces Shareholders Approve All Board Proposals at the Annual General Meeting
13. April 2022 09:00 ET
|
Molecular Partners
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., April 13, 2022 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of...
Molecular Partners Announces Publication of Preclinical Data from CD40 Therapeutic Candidate MP0317 in Cancer Immunology Research
24. März 2022 02:00 ET
|
Molecular Partners
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 24, 2022 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of...
Molecular Partners Publishes Invitation to Annual General Meeting 2022
17. März 2022 01:00 ET
|
Molecular Partners
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 17, 2022 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN, NASDAQ: MOLN), a clinical-stage biotech company developing a new class of...
Molecular Partners Reports Corporate Highlights From Q4 2021 and Key Financials for Full Year 2021
15. März 2022 16:30 ET
|
Molecular Partners
Research & Development Highlights: In January of 2022, announced positive topline results from Phase 2 EMPATHY clinical trial of ensovibep for the treatment of non-hospitalized COVID-19 patients,...
Molecular Partners to Present at Upcoming Healthcare Investor Conferences
25. Februar 2022 16:30 ET
|
Molecular Partners
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Feb. 25, 2022 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of...
Molecular Partners to Present at Upcoming Healthcare Investor Conference
11. Februar 2022 16:10 ET
|
Molecular Partners
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of...